Tenax Therapeutics, Inc. (TENX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Tenax Therapeutics reported revenue of $0. Net income was -$52.6M, or -$1.34 per diluted share. Operating activities generated -$35.8M of cash. At fiscal year end, Tenax Therapeutics held $104.2M in total assets against $7.2M in total liabilities, including $97.6M of cash and equivalents.
Open the full interactive Tenax Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Tenax Therapeutics Key Stats
| Share Price | $1.60 |
|---|---|
| Market Cap | $81.4M |
| 52-Week Range | $1.38 – $18.32 |
| Shares Outstanding | 50.9 million (basic, 2026 Q2) |
Tenax Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$9.9M | $32.7M | -$11.1M | $8.2M | -$19.5M | -$56.4M |
| Pre-Tax Income | -$9.9M | -$32.5M | -$11.0M | $7.7M | -$17.6M | -$52.6M |
| Income Tax | $0 | $0 | $0 | — | $0 | $0 |
| Net Income | -$9.9M | -$32.5M | -$11.0M | $7.7M | -$17.6M | -$52.6M |
| Diluted EPS | -$2128.00 | -$2528.00 | — | — | -$1.15 | -$1.34 |
Tenax Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$15.8M | -$15.5M | -$15.7M | -$17.8M |
| Diluted EPS | -$0.40 | -$0.40 | -$0.35 | -$0.35 |
Tenax Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.3M | $5.6M | $2.1M | — | $94.9M | $97.6M |
| Current Assets | $6.8M | $5.7M | $3.2M | $11.7M | $96.7M | $104.2M |
| Total Assets | $6.9M | $6.0M | $3.4M | $11.7M | $96.7M | $104.2M |
| Current Liabilities | $2.1M | $1.6M | $1.8M | $3.6M | $4.7M | $7.2M |
| Total Long-Term Debt | $244,657 | — | — | — | — | — |
| Total Liabilities | $2.2M | $1.7M | $1.9M | $3.6M | $4.7M | $7.2M |
| Shareholders' Equity | $4.6M | $4.2M | $1.5M | $8.1M | $92.0M | $97.1M |
Tenax Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$9.3M | -$10.9M | -$12.0M | -$5.9M | -$14.8M | -$35.8M |
| Cash From Investing | $20,109 | $452,609 | -$2,323 | $2,843 | $0 | — |
| Cash From Financing | $10.6M | $9.7M | $8.6M | $13.6M | $99.9M | $38.5M |
| Free Cash Flow | -$9.3M | -$10.9M | -$12.0M | — | -$14.8M | — |
Figures from Tenax Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Tenax Therapeutics financials page for every line item.
Tenax Therapeutics Company Profile
| Ticker | TENX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Chapel Hill, North Carolina |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000034956 |
Frequently Asked Questions
What was Tenax Therapeutics' revenue in fiscal 2025?
Tenax Therapeutics (TENX) reported revenue of $0 for fiscal 2025.
What is Tenax Therapeutics' annual revenue history?
Tenax Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Tenax Therapeutics' net income in fiscal 2025?
Tenax Therapeutics reported net income of -$52.6M for fiscal 2025.
What was Tenax Therapeutics' earnings per share (EPS) in fiscal 2025?
Tenax Therapeutics' diluted EPS was -$1.34 for fiscal 2025 (adjusted for any later stock splits).
What was Tenax Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Tenax Therapeutics reported revenue of $0.
How many shares of Tenax Therapeutics are outstanding?
Tenax Therapeutics reported a weighted average of 50.9 million basic shares outstanding in 2026 Q2.
What is Tenax Therapeutics' market cap?
Based on its latest closing price, Tenax Therapeutics (TENX) has a market capitalization of about $81.4M.
When does Tenax Therapeutics' fiscal year end?
Tenax Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Tenax Therapeutics headquartered?
Tenax Therapeutics lists its business address in Chapel Hill, North Carolina in its SEC filings.